| 1 Mortality at any time point |
3 |
146 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 1.1 at 1 year |
2 |
128 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 1.2 at 2 years |
1 |
18 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 2 Incidence of thyroid disease at end of study |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
| 3 ALT (U/L): mean change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 4 AST (U/L): mean change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 5 Urea (mg/dL): mean change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 6 Creatinine (mg/dL): mean change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 7 Neutrophil (count per mm³): mean change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 8 Serum ferritin (ng/mL): mean change from baseline and at end of study |
2 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 8.1 All participants |
2 |
83 |
Mean Difference (IV, Fixed, 95% CI) |
229.99 [‐403.14, 863.11] |
| 8.2 Ferritin > 4000 |
1 |
11 |
Mean Difference (IV, Fixed, 95% CI) |
1129.0 [‐2226.18, 4484.18] |
| 8.3 Ferritin 2000 ‐ 4000 |
1 |
16 |
Mean Difference (IV, Fixed, 95% CI) |
‐151.0 [‐743.80, 441.80] |
| 8.4 Ferritin < 2000 |
1 |
11 |
Mean Difference (IV, Fixed, 95% CI) |
388.0 [‐255.71, 1031.71] |
| 9 LIC (mg/g) evaluated by MRI (R2*): mean change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 10 Myocardial T2* (ms): mean change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 11 Any AE (# participants affected) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
| 12 AEs |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
| 12.1 GI disorders ‐ diarrhoea |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.2 GI disorders ‐ nausea |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.3 GI disorders ‐ pain abdomen |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.4 GI disorders ‐ vomiting |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.5 Musculoskeletal and connective tissue disorders ‐ arthralgia |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.6 Skin and subcutaneous tissue disorders ‐ rash |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.7 Blood and lymphatic system disorder ‐ agranulocytosis |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.8 Blood and lymphatic system disorder ‐ neutropenia |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.9 Investigations ‐ AST levels > 2x UNL |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.10 Investigations ‐ ALT levels > 2x UNL |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.11 Investigations ‐ serum creatinine 50% increase from baseline |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 12.12 Renal and urinary disorders ‐ renal failure |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
0.0 [0.0, 0.0] |
| 13 Discontinuations (# participants affected) |
3 |
179 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.16 [0.01, 2.99] |
| 14 Discontinuation due to an AE (# participants affected) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Totals not selected |
| 15 Transferrin saturation (%): mean at end of study |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 16 Haemoglobin (g/dL): mean at end of study |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 17 Transfusion index (mL/kg/year): mean at end of study |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 18 ALP (U/L): mean change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
